CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma

Table 1 Baseline characteristics, n (%)

Characteristics	Overall (n = 192)	CRAFITY-high (n = 40)	CRAFITY-intermediate (n = 102)	CRAFITY-low (n = 50)	P value
Age, median [IQR]	57.5 [50.0, 64.0]	61.0 [55.0, 64.0]	56.0 [50.0, 62.0]	56.5 [50.2, 64.0]	0.0746
Sex					0.5933
Male	161 (83.9)	33 (82.5)	88 (86.3)	40 (80.0)
Female	31 (16.1)	7 (17.5)	14 (13.7)	10 (20.0)
ECOG PS					0.0071
0	114 (59.4)	20 (50.0)	55 (53.9)	39 (78.0)
1	78 (40.6)	20 (50.0)	47 (46.1)	11 (22.0)
Cause					0.2466
HBV	166 (86.5)	38 (95.0)	85 (83.3)	43 (86.0)
HCV	15 (7.8)	2 (5.0)	8 (7.8)	5 (10.0)
Others	11 (5.7)	0 (0.0)	9 (8.8)	2 (4.0)
Cirrhosis	160 (83.3)	35 (87.5)	85 (83.3)	40 (80.0)	0.6376
Resection	30 (15.6)	4 (10.0)	19 (18.6)	7 (14.0)	0.4153
TACE	166 (86.5)	31 (77.5)	87 (85.3)	48 (96.0)	0.0343
Ablation	80 (41.7)	12 (30.0)	46 (45.1)	22 (44.0)	0.241
Treatment line					0.505
First	147 (76.6)	33 (82.5)	78 (76.5)	36 (72.0)
Later	45 (23.4)	7 (17.5)	24 (23.5)	14 (28.0)
Number					0.2285
< 3	73 (38.0)	13 (32.5)	36 (35.3)	24 (48.0)
≥ 3	119 (62.0)	27 (67.5)	66 (64.7)	26 (52.0)
Size					0.0149
< 5 cm	66 (34.4)	6 (15.0)	40 (39.2)	20 (40.0)
≥ 5 cm	126 (65.6)	34 (85.0)	62 (60.8)	30 (60.0)
PVTT	101 (52.6)	28 (70.0)	45 (44.1)	28 (56.0)	0.018
EHM	90 (46.9)	18 (45.0)	51 (50.0)	21 (42.0)	0.627
Child-Pugh					0.9888
Grade A	128 (66.7)	27 (67.5)	68 (66.7)	33 (66.0)
Grade B	64 (33.3)	13 (32.5)	34 (33.3)	17 (34.0)
BCLC					0.1836
Stage B	34 (17.7)	5 (12.5)	16 (15.7)	13 (26.0)
Stage C	158 (82.3)	35 (87.5)	86 (84.3)	37 (74.0)

ECOG PS: Eastern Cooperative Oncology Group performance status; HBV: Hepatitis B virus; HCV: Hepatitis C virus; TACE: Transarterial chemoembolization; PVTT: Portal vein tumor thrombosis; EHM: Extrahepatic metastasis; BCLC: Barcelona Clinic Liver Cancer.